X-linked spasticity-intellectual disability-epilepsy syndrome

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:3175OMIM:308350G25.3
Who is this for?
Show terms as
1Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

X-linked spasticity-intellectual disability-epilepsy syndrome (also known as Goldblatt syndrome or X-linked spastic paraplegia-intellectual disability-epilepsy syndrome) is a rare genetic neurological disorder that primarily affects males. The condition is characterized by a triad of progressive spastic paraplegia (stiffness and weakness of the legs), intellectual disability of variable severity, and epileptic seizures. The central nervous system is the primary body system affected, with symptoms reflecting dysfunction of both the upper motor neurons (leading to spasticity) and the cerebral cortex (contributing to seizures and cognitive impairment). Affected individuals typically present in infancy or early childhood with developmental delay, followed by the emergence of spasticity in the lower limbs and seizures. The spasticity may be progressive and can significantly impair mobility over time. Intellectual disability ranges from mild to severe. Seizures may take various forms and can be difficult to control with standard antiepileptic medications. Female carriers may be asymptomatic or show mild manifestations due to X-inactivation patterns. There is currently no cure for this condition. Treatment is symptomatic and supportive, focusing on management of spasticity through physical therapy and antispasticity medications (such as baclofen), seizure control with antiepileptic drugs, and educational and developmental support services to optimize cognitive and functional outcomes. Orthopedic interventions may be necessary in some cases to address contractures or skeletal deformities resulting from chronic spasticity.

Clinical phenotype terms— hover any for plain English:

HemiplegiaHP:0002301
Inheritance

X-linked recessive

Carried on the X chromosome; typically affects males more than females

Age of Onset

Infantile

Begins in infancy, roughly 1 month to 2 years old

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for X-linked spasticity-intellectual disability-epilepsy syndrome.

View clinical trials →

No actively recruiting trials found for X-linked spasticity-intellectual disability-epilepsy syndrome at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the X-linked spasticity-intellectual disability-epilepsy syndrome community →

Specialists

1 foundView all specialists →

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to X-linked spasticity-intellectual disability-epilepsy syndrome.

Search all travel grants →NORD Financial Assistance ↗

Community

Open X-linked spasticity-intellectual disability-epilepsy syndromeForum →

No community posts yet. Be the first to share your experience with X-linked spasticity-intellectual disability-epilepsy syndrome.

Start the conversation →

Latest news about X-linked spasticity-intellectual disability-epilepsy syndrome

No recent news articles for X-linked spasticity-intellectual disability-epilepsy syndrome.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about X-linked spasticity-intellectual disability-epilepsy syndrome

What is X-linked spasticity-intellectual disability-epilepsy syndrome?

X-linked spasticity-intellectual disability-epilepsy syndrome (also known as Goldblatt syndrome or X-linked spastic paraplegia-intellectual disability-epilepsy syndrome) is a rare genetic neurological disorder that primarily affects males. The condition is characterized by a triad of progressive spastic paraplegia (stiffness and weakness of the legs), intellectual disability of variable severity, and epileptic seizures. The central nervous system is the primary body system affected, with symptoms reflecting dysfunction of both the upper motor neurons (leading to spasticity) and the cerebral co

How is X-linked spasticity-intellectual disability-epilepsy syndrome inherited?

X-linked spasticity-intellectual disability-epilepsy syndrome follows a x-linked recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does X-linked spasticity-intellectual disability-epilepsy syndrome typically begin?

Typical onset of X-linked spasticity-intellectual disability-epilepsy syndrome is infantile. Age of onset can vary across affected individuals.

Which specialists treat X-linked spasticity-intellectual disability-epilepsy syndrome?

1 specialists and care centers treating X-linked spasticity-intellectual disability-epilepsy syndrome are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.